Spona J, Kolb R, Reiner G, Jakesz R, Moser K, Rainer H
Cancer Detect Prev. 1983;6(1-2):227-34.
Estrogen (ER) and progesterone (PgR) receptor contents were determined in 214 patients with primary mammary carcinoma. Premenopausal and postmenopausal females (43 and 48%, respectively) were found to be ER and PgR positive. ER levels between 100 and 500 fmol/mg protein were observed in 37% postmenopausal and 14% premenopausal patients, respectively. ER distribution between lymph node-positive and -negative patients did not differ significantly. Subjects without detectable ER had recurrences earlier than did subjects with ER. On the other hand, no differences in recurrence rates were noted when PgR-positive and -negative patients were compared. In addition, the determination of ER did not permit selection of patients for adjuvant cytotoxic chemotherapy. Furthermore, the action of tamoxifen was investigated in the rat pituitary as a model system. Tamoxifen was found to act as antiestrogen at the level of transcription by inhibiting the accumulation of estrogen-stimulated preprolactin mRNA. Combined data suggest that patients with positive lymph nodes and positive receptors may benefit from combined endocrine plus cytotoxic adjuvant chemotherapy.
对214例原发性乳腺癌患者进行了雌激素（ER）和孕激素（PgR）受体含量测定。结果发现，绝经前和绝经后女性中ER和PgR阳性者分别占43%和48%。绝经后和绝经前患者中，分别有37%和14%的患者ER水平在100至500 fmol/mg蛋白质之间。ER在淋巴结阳性和阴性患者中的分布无显著差异。未检测到ER的患者比有ER的患者复发更早。另一方面，比较PgR阳性和阴性患者时，未发现复发率有差异。此外，ER的测定不能用于选择辅助细胞毒性化疗的患者。此外，以大鼠垂体作为模型系统研究了他莫昔芬的作用。发现他莫昔芬在转录水平上作为抗雌激素发挥作用，通过抑制雌激素刺激的前催乳素mRNA的积累。综合数据表明，淋巴结阳性且受体阳性的患者可能从内分泌加细胞毒性联合辅助化疗中获益。
